Partnering in CardioMetabolic Diseases
Our growing portfolio of partnerships in CardioMetabolic diseases spans the discovery and development value chain and includes partnerships with academia and industry including our long-standing, global strategic alliance with Eli Lilly and Company established in 2011. We are actively pursuing new early-science collaborations in our areas of partnering interest and look forward to expanding our community of innovation partners in CardioMetabolic diseases.
Our experience
Our innovation in CardioMetabolic diseases is evidenced by our track record of excellence in research and landmark clinical trials which have resulted in important achievements in recent years, especially in thromboembolic diseases and type 2 diabetes.
Our portfolio of marketed products for CardioMetabolic diseases includes treatments for:
- Thromboembolic diseases
- Type 2 diabetes
- Acute myocardial infarction
- Hypertension
- Cardio-renal risk-reduction.
Scientists in our research and development centers for CardioMetabolic diseases in Germany and the USA, are working with many academic and industry partners to discover and develop breakthrough treatments that continue our tradition of innovation excellence in CardioMetabolic disease research.
Our research focus
Our CardioMetabolic research strategy takes a holistic view of the broader therapeutic needs of patients who may often have multiple conditions, connected by underlying similar pathologies. This approach gives us the opportunity to take a broad perspective and explore a number of different research fields, allowing us to prioritize the most promising avenues of discovery and create synergies across our research programs.
Current research efforts focus on new strategies for the treatment of diabetes, obesity, non-alcoholic steatohepatitis, diabetic eye diseases and chronic kidney disease.